Myokines and cognitive aging in people with spinal cord injury: a single case experimental design study

Conditions: myelopathy
spinal cord injury
10041543

Registration Number: NL-OMON56022

Lead Sponsor: Medisch Universitair Ziekenhuis Maastricht

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Pending

Sex: Not specified

Target Recruitment: 15

Inclusion Criteria

-Persons with spinal cord injury
-Completeness of injury: AIS A, B or C
-Level of injury: L2 or higher
-At least 18 years old
-Chronic stage (> 1 year) since injury
-No previous surgery to the quadriceps muscles
-Able to use apps on smartphone (i.e. participants should have their own
smartphone and should not have disabilities that impair them to operate it
independently)
-Able to follow the instructions of placing the surface electrodes of the NMES
device correctly or to have someone else put the electrodes for them
-Dutch as a native language

Exclusion Criteria

-Malignant processes, or history of undergoing chemotherapy, or history of
radiotherapy to the head
-No visible or palpable contraction of the quadriceps muscle upon electrical
stimulation
-Intolerance to electrical stimulation of the quadriceps muscle
-Recent or current participation in an electrical stimulation-induced exercise
or therapy program in which regular electrical stimulation was given (up to 6
months prior to study inclusion)
-Known neurodegenerative disorder, such as Alzheimer*s disease or Parkinson*s
disease
-Known psychiatric disorder, such as major depressive disorder or bipolar
disorder
-Current pressure ulcer
-History of severe autonomic dysreflexia
-Metal implants in the electrical stimulation area
-Intrathecal baclofen (ITB) device
-Pregnancy

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Response time and %accuracy on an executive function task</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>A cognitive test battery and blood collection for the assessment of<br /><br>Brain-derived neurotrophic factor (BDNF) levels. Other measured variables are<br /><br>important for taking into account potential moderating effects.</p><br>